Free tool
FAERS Monitor: Imcivree
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213793 or its brand name (Imcivree, Setmelanotide Acetate). Reports on generic versions are filed under their own applications.
Reports
285
Serious
187
66% of reports
Hospitalization
106
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea81
- off label use79
- skin hyperpigmentation64
- vomiting43
- headache42
- diarrhoea38
- fatigue36
- skin discolouration35
- decreased appetite27
- melanocytic naevus25
- weight increased25
- abdominal pain23
- injection site pruritus23
- injection site erythema22
- injection site pain22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 22 |
| 2022 | 9 |
| 2023 | 32 |
| 2024 | 33 |
| 2025 | 133 |
| 2026 | 55 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,874 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin hyperpigmentationSignal | 64 | 553.7 | 445.8 | 34,517 |
| melanocytic naevusSignal | 25 | 423.2 | 290.7 | 10,057 |
| skin discolourationSignal | 35 | 56.2 | 41.2 | 1,847 |
| injection site pruritusSignal | 23 | 25.3 | 17.1 | 515 |
| injection site erythemaSignal | 22 | 13.1 | 8.8 | 235 |
| decreased appetiteSignal | 27 | 8.6 | 6.0 | 175 |
| weight increasedSignal | 25 | 8.2 | 5.7 | 153 |
| nauseaSignal | 81 | 7.6 | 6.3 | 472 |
| abdominal painSignal | 23 | 7.3 | 4.9 | 120 |
| vomitingSignal | 43 | 6.7 | 5.1 | 210 |
| off label useSignal | 79 | 6.7 | 5.5 | 390 |
| injection site painSignal | 22 | 5.3 | 3.5 | 73 |
| headacheSignal | 42 | 4.9 | 3.7 | 132 |
| diarrhoeaSignal | 38 | 4.3 | 3.2 | 98 |
| fatigueSignal | 36 | 3.4 | 2.5 | 61 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.